InferVision has received U.S. Food and Drug Administration (FDA) clearance for InferCare RECIST, bringing AI-powered, standardized tumor assessment into routine oncology workflows.

InferCare RECIST assists clinicians in evaluating tumor response based on RECIST criteria, replacing time-consuming manual measurements with automated, reproducible analysis. By enabling consistent lesion measurement and longitudinal tracking across timepoints, the solution helps streamline workflows and reduce variability in clinical practice.

Designed for real-world oncology settings, InferCare RECIST supports more efficient treatment monitoring and more confident decision-making across care teams.

“This FDA clearance represents a key step in advancing AI-driven oncology imaging,” said Matt, Head of InferVision US Team. “InferCare RECIST enables clinicians to standardize tumor assessment at scale and focus more on patient care.”

The software is intended for use by radiologists, oncologists, and other trained healthcare professionals, and integrates seamlessly into existing clinical workflows.

With this clearance, InferVision continues to expand its portfolio of FDA-cleared AI solutions across lung cancer screening, thoracic imaging, and oncology.

‍